AtriCure director Regina E. Groves sold 5,313 shares at $54.22 per share, representing about 13.3% of her prior holding. She retained 34,546 AtriCure shares after the transaction, giving investors a clear view of the director’s remaining ownership following the sale.
Key Highlights
- The transaction occurred on September 11, 2026, under transaction code S.
- Regina E. Groves held 34,546 AtriCure shares after the sale.
- The transaction represented about 13.3% of her prior shareholding.
AtriCure, Inc. (NASDAQ: ATRC) director Regina E. Groves sold 5,313 shares at $54.22 per share, representing about 13.3% of her prior holding. Groves retained 34,546 AtriCure shares after the transaction.
September 11 Director Stock Sale
The transaction took place on September 11, 2026, and identified Groves as a director of AtriCure. The filing lists SEC transaction code S for the sale. The reported price was $54.22 for each share transferred. AtriCure’s director transaction involved 5,313 shares. The disclosure identifies Regina E. Groves as the individual conducting the sale. The transaction was reported through the company’s official regulatory disclosure. Transaction code S denotes an open-market or private sale.
FAQs
Q: How many AtriCure shares did Regina E. Groves sell?
A: AtriCure director Regina E. Groves sold 5,313 shares in the reported transaction. The filing states that the shares were sold at $54.22 per share.
Q: What was the impact of the AtriCure director stock sale?
A: The sale represented about 13.3% of Groves’ prior AtriCure holding. The filing states that she retained 34,546 shares after the transaction.
Q: When did the AtriCure insider transaction occur?
A: The AtriCure director transaction occurred on September 11, 2026. The filing identifies Regina E. Groves as the director involved and reports SEC transaction code S for the sale.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.